Redeye positively views today's news that Xbrane's filing has been accepted by the FDA.
Redeye comments on the positive readout from the phase I/IIa trial with the anti-TNFR2 antibody BI-1...
Lansering av SCIZYS har skjutits fram eftersom kompletteringar behöver göras.
Redeye comments on the new patent application for partial degradation and purification of PFAS in wa...
Endomines agreed on convertible loan financing with Finnish investors to start production at Hosko a...
Redeye comments on Better Collective’s upgraded financial targets for 2023E which the company has in...
Anette Billing resigns as CEOChairman, Sverre Bjerkeli takes over as interim CEOSearch for a new CEO...
SEK 875m directed share issue Proforma deleveraging from ~3.
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...
Analyst Group has initiated equity research coverage of Huddlestock, including equity research repor...
CirChems intäkter uppgick till 564 KSEK under Q1-23, att jämföra med 366 KSEK under föregående kvart...
Investeringsbolaget Katalysen Ventures redovisade minskad nettoomsättning och EBIT i det första kvar...
Double Bond Pharma är framme i ett intressant läge där dess läkemedelskandidat SI-053 för behandling...
Redeye initiates coverage of Avensia, a premium e-commerce-focused IT consultancy firm, which combin...
Q2 report due 19 July Q2'23e sales of SEK 195m, adj.
Vi återtar bevakning efter den nyss avslutade nyemissionen, som innebar att bolaget tillförs 180 mkr...
Stark avslutning på 2022/23 ScandiDos redovisar fortsatt momentum i Asien under Q4, vilket bidrog ti...
Kvartalsrapporten visar på trendbrott i återkommande intäkter & Divio förlänger kontraktet med stork...
There was plenty of IgAN attention including new and emerging treatment modalities.
Redeye updates its view on Energy Save (ES) post the Q4 2022/23 report.
